Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06355934 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06355934 · ClinicalTrials.gov record · last posted 2026-08-11

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

Name: OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis — clinical trial record (NCT06355934)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: OverTTuRe

StatusRecruiting

PhaseNot specified

SponsorAstraZeneca

Started2023-08-21

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.

Protocol amendment history 3 changes detected by DataLookout

2026-08-12

Primary completion pushed: 2026-09-30 → 2026-11-02

2026-08-12

Completion pushed: 2026-09-30 → 2026-11-02

2026-07-19

Trial sites expanded: 26 → 29 locations

Trial Details

NCT Number	NCT06355934
Lead Sponsor	AstraZeneca
Conditions	ATTR Amyloidosis
Enrollment	52,121 participants
Start Date	2023-08-21
Primary Completion	2026-11-02 (estimated)
Study Completion	2026-11-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-11